ArticleNeurosurgery2020
The Ki-67 Proliferation Index as a Marker of Time to Recurrence in Intracranial Meningioma.
Article in Neurosurgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- A systematic review of radiological prediction of ki 67 proliferation index of meningioma.Neurosurgical review · 2024Pooled it
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.Neurosurgical review · 2022Pooled it
- Adjuvant radiotherapy and stereotactic radiosurgery in grade 3 meningiomas - a systematic review and meta-analysis.Neurosurgical review · 2022Pooled it
- Research progress of deep learning based on magnetic resonance imaging in meningioma.Magma (New York, N.Y.) · 2026Review
- Time-dependent prognostic value of automated Ki67 assessment and its integration with molecular risk profiling in WHO grade 2 meningioma.Acta neuropathologica communications · 2026Article
- Lactobacillus-derived indole-3-lactic acid suppresses meningioma malignant phenotypes by direct anti-proliferative effects and macrophage reprogramming.Journal of translational medicine · 2026Article
- Attention-based deep learning network for predicting World Health Organization meningioma grade and Ki-67 expression based on magnetic resonance imaging.European radiology · 2026Article
- Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.Acta neuropathologica communications · 2025Article
- MRI-based multiregional radiomics for preoperative prediction of Ki-67 expression in meningiomas: a two-center study.Frontiers in neurology · 2025Article
- AreFrontiers in endocrinology · 2025Article
- Benign extracranial meningioma with pulmonary metastasis: a case report and review of literature.Journal of medical case reports · 2024Review
- Single versus multiple reoperations for recurrent intracranial meningiomas.Journal of neuro-oncology · 2024Article
- Surgical Outcomes following Reoperation for Recurrent Intracranial Meningiomas.Journal of clinical medicine · 2024Article
- A comprehensive correlation of the KI-67 proliferation index to patient´s, imaging and tumor features and its value in predicting long-term course of patients with newly diagnosed intracranial meningiomas.Neurosurgical review · 2024Article
- An MRI-Based Deep Transfer Learning Radiomics Nomogram to Predict Ki-67 Proliferation Index of Meningioma.Journal of imaging informatics in medicine · 2024Article
- Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery.Journal of neuro-oncology · 2024Article
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Novel Postoperative Serum Biomarkers in Atypical Meningiomas: A Multicenter Study.Neurosurgery · 2023Article
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are examples of incongruence between the WHO grade and clinical course in meningioma patients. This incongruence between WHO grade and recurrence has led to search for other prognostic histological markers.
objectiveTo study the correlation between the Ki-67 proliferative index (PI), risk of recurrence, and recurrence rates in meningioma patients.
methodsWe prospectively collected pathological diagnosis of de novo consecutive meningiomas. In total, we followed 159 patients with clinical controls until recurrence, death, or emigration. We estimated the correlation between risk of recurrence and Ki-67 PI when adjusted for age at diagnosis, sex, WHO grade, extent of surgical resection, and tumor location. We estimated the cumulative incidence of recurrence when considering death without recurrence a competing risk. We report recurrence rates per 100 person-years.
resultsA 1%-point increase of Ki-67 PI yielded a hazard ratio of 1.12 (95% CI: 1.01-1.24) in a multivariate analysis. The cumulative incidence of recurrence was 3% for Ki-67 0% to 4% vs 19% for Ki-67 > 4% meningiomas after 1 yr, but 24% vs 35%, respectively, after 10 yr. There was no significant difference in mean Ki-67 PI between nonrecurrent and recurrent meningioma in a 2-sample t-test (P = .08). The strongest relationship was detected between Ki-67 PI and time to recurrence: Ki-67 < 4% meningiomas recurred after median 4.8 yr, compared to 0.60 to 0.75 yr for patients with higher Ki-67 PI.
conclusionKi-67 PI was a marker for time to recurrence rather than a predictor of recurrence. Ki-67 PI may be utilized for patient tailored follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.